{"transactions":[{"id":737799,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Preferred Stock","published_at":"2026-06-15T21:35:38.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":8111,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series F Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series F Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series F Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series F Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5271},"source":{"system":"sec-edgar","filing":"0001193125-26-271344","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271344/ownership.xml","form_type":"4"}},{"id":737798,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-06-15T21:35:38.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":3666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3878},"source":{"system":"sec-edgar","filing":"0001193125-26-271344","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271344/ownership.xml","form_type":"4"}},{"id":737797,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-15T21:35:38.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":5332,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5539},"source":{"system":"sec-edgar","filing":"0001193125-26-271344","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271344/ownership.xml","form_type":"4"}},{"id":737796,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:35:38.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":5271,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series F Preferred Stock had no expiration date."}],"balance_after":14688,"source":{"system":"sec-edgar","filing":"0001193125-26-271344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271344/ownership.xml","form_type":"4"}},{"id":737795,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:35:38.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":3878,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series C Preferred Stock had no expiration date."}],"balance_after":9417,"source":{"system":"sec-edgar","filing":"0001193125-26-271344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271344/ownership.xml","form_type":"4"}},{"id":737794,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:35:38.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":5539,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Series B Preferred Stock had no expiration date."}],"balance_after":5539,"source":{"system":"sec-edgar","filing":"0001193125-26-271344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271344/ownership.xml","form_type":"4"}},{"id":741688,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:48:05.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":20215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":20215,"derivative":{"exercise_price":20,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":20215},"source":{"system":"sec-edgar","filing":"0001193125-26-267769","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526267769/ownership.xml","form_type":"4"}},{"id":3485926,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-18T20:31:58.000Z","date":"2019-06-14","kind":"grant","acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest over a four year period in equal annual installments beginning on June 14, 2019."}],"balance_after":26400,"derivative":{"exercise_price":22.74,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-19-037700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242993/000120919119037700/doc4.xml","form_type":"4"}},{"id":3904900,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":38173,"kind":"person","name":"FITZGERALD EDWARD M","position":1,"cik":"0001242993","reported_name":"FITZGERALD EDWARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-05T20:06:55.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest over a four year period in equal annual installments beginning on June 1, 2018."}],"balance_after":26400,"derivative":{"exercise_price":23.46,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-18-035591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242993/000120919118035591/doc4.xml","form_type":"4"}}]}